nct_id: ACT017
nct_purpose: >-
  (1) ORR, as assessed by BICR using RECIST 1.1, in each subject population expansion cohort. (2) The DOR, TTR and CBR will be assessed by BICR using RECIST 1.1. (3) The PFS and OS will be assessed by BICR using RECIST 1.1. (4) Intracranial ORR and CNS-PFS will be assessed by BICR. (5) Type, incidence, severity, timing, seriousness, and relatedness of AEs and laboratory abnormalities. (6) Pharmacokinetic parameters of repotrectinib. (7) Changes in Quality-of-Life and health status during repotrectinib treatment.
age: Adults
cancer_center_accrual_goal_upper: 0
data_table4: "Interventional"
drug_list:
  drug:
    - drug_name: TPX-0005 (Repotrectinib)
long_title: >-
  A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety,
  Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in
  Patients with Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3
  Rearrangements
management_group_list:
  management_group:
    - is_primary: 'Y'
      management_group_name: CUHKOncology
oncology_group_list:
  oncology_group:
    - group_name: Group1
      is_primary: 'N'
phase: '1/2'
principal_investigator: Dr. Herbert Loong
principal_investigator_institution: CUHK
program_area_list:
  program_area:
    - is_primary: 'Y'
      program_area_name: Program 1
protocol_id: 0
protocol_no: '{{protocol_no}}'
protocol_target_accrual: 0
protocol_type: "Interventional"
prior_treatment_requirements:
  - >-
    Histologically or cytologically confirmed diagnosis of locally advanced or
    metastatic solid tumor (including primary CNS tumors) that harbors a ROS1,
    ALK, or NTRK1-3 gene fusion.
  - >-
    Subjects must have a documented ROS1, ALK or NTRK1-3 gene fusion identified
    by local testing AND confirmed by a central diagnostic laboratory prior to
    enrollment.
short_title: >-
  Phase 1/2 Study of Repotrectinib in Solid Tumors with ALK, ROS1, or NTRK
  Rearrangements
site_list:
  site: []
sponsor_list:
  sponsor: []
staff_list:
  protocol_staff: []
status: open to accrual
summary: ''
treatment_list:
  step:
    - step_code: '1'
      step_type: Registration
      step_internal_id: 111
      arm:
        - arm_code: Arm A
          arm_internal_id: 1
          arm_description: 'General arm for ALK/ROS1/NTRK'
          arm_suspended: 'N'
      match:
        - and:
            - clinical:
                oncotree_primary_diagnosis: _SOLID_
            - clinical:
                disease_status:
                  - Advanced
            - or:
                - genomic:
                    hugo_symbol: ALK
                    variant_category: Structural Variation
                - genomic:
                    hugo_symbol: ROS1
                    variant_category: Structural Variation
                - genomic:
                    hugo_symbol: NTRK1
                    variant_category: Structural Variation
                - genomic:
                    hugo_symbol: NTRK2
                    variant_category: Structural Variation
                - genomic:
                    hugo_symbol: NTRK3
                    variant_category: Structural Variation
